Record ¥106.9bn profit, stock at half its high: what Sumitomo Pharma earns once the one-offs and dilution are stripped out

For the fiscal year ended March 2026, Sumitomo Pharma reported net income attributable to owners of the parent of ¥106.9bn, up 352.2% year on year. Two years earlier, in FY2024 (March), it lost roughly ¥315bn. On paper, that is a textbook V-shaped recovery.

The stock tells a different story. It peaked at 3,288 yen in February 2026 and has drifted to around 1,600 yen in September, less than half the high and still below the 1,990 yen price of April’s public offering. Record profit, half-price stock: is the market misreading the recovery, or is the record profit weaker than it looks? This note answers that by stripping out one-off gains and dilution and asking what earning power is left.

A turnaround drugmaker that lives on two U.S. oral drugs

Sumitomo Pharma is a consolidated subsidiary of Sumitomo Chemical. It is an R&D-driven drugmaker that earns most of its money by selling two products through its own U.S. sales force: ORGOVYX for advanced prostate cancer and GEMTESA for overactive bladder. In Japan it fills out revenue by co-promoting other companies’ drugs. In regenerative and cell medicine, its iPS cell–derived Parkinson’s disease product received conditional, time-limited approval in Japan in March 2026.

Both U.S. drugs have real clinical differentiation. ORGOVYX is the only oral option in hormone therapy. A January 2025 cap on Medicare out-of-pocket costs nearly doubled volumes, and sales reached about $1bn (+88%). GEMTESA is the only β3 agonist approved for overactive bladder in men with benign prostatic hyperplasia, and sales reached about $0.6bn (+45%). Generic entry for a competing product has also widened the β3 agonist market as a whole.

The flip side is concentration. According to the annual securities report, North American sales of the two drugs make up 55% of consolidated revenue. The Inflation Reduction Act (IRA), most-favored-nation (MFN) drug pricing, tariffs, and insurance coverage changes all flow straight into profit. Exclusivity has already ended for APTIOM in the U.S. and the type 2 diabetes drugs Equa and EquMet in Japan, and the two oncology assets meant to follow ORGOVYX and GEMTESA, enzomenib and nuvisertib, are still in clinical development.

Revenue up about 44%, but almost half of core profit came once

Revenue rose from ¥314.56bn in 2024 to ¥453.29bn in 2026, about 44% in two years. By segment, North America grew to ¥337.9bn (+34.2%), while Japan fell to ¥92.4bn (−7.5%) and Asia shrank to ¥23.0bn (−51.2%) after part of the business was sold and deconsolidated. Nearly all the growth came from the two U.S. drugs plus a sales milestone payment on ORGOVYX.

The profit recovery mixes structural and one-time elements. The structural part is cost: headcount fell from 4,980 in 2024 to 3,123 in 2026, and revenue per employee more than doubled, from about ¥63.2m to about ¥145.1m.

The one-time part is large. In FY2026 the company booked a ¥49.0bn gain on the partial sale of its Asia business as other income within core operating profit. That is about 46% of core operating profit of ¥105.9bn. The ORGOVYX sales milestone is also in there, but its size is not disclosed. Management itself guides FY2027 (March) to revenue of ¥540.0bn (+19.1%) but net income of ¥77.0bn (−27.9%). That is company guidance and is not used in the tables here. A 23.6% net margin should not be read as the run rate.

About 2x market cap even without the one-off, yet the market still discounts it

(* Simulation assumptions: estimated share price 1,595 yen, required return 5%)

Owner earnings here are net income plus depreciation and amortization, minus capital expenditure and intangible asset investment. FY2026 owner earnings were ¥120.34bn; capitalized at a 5% required return, owner earnings value is ¥2,406.78bn. That is about 3.4x the simulated market cap of ¥715.51bn (1,595 yen × 448,593,454 post-offering shares, excluding treasury stock).

But that ¥120.34bn includes one-offs. okuriru’s adjusted owner earnings, which remove ¥46.97bn of one-time items, come to ¥73.37bn, for an adjusted owner earnings value of ¥1,467.38bn. Simply subtracting the ¥49.0bn gain from the securities report gives about ¥71.3bn, so the conclusion barely moves. Even after stripping the one-off, a 5% required return implies value of about 2x market cap.

So why does the market discount it so heavily? Working backward, adjusted owner earnings of ¥73.37bn equal about 10.3% of the simulated market cap. Add the roughly ¥287bn of negative net cash covered in the next section, and the yield is still about 7.3%. In other words, the market is asking for something like 7–10% from Sumitomo Pharma, not 5%. For a company that relies on two drugs for 55% of revenue and sits directly in the path of U.S. drug-pricing policy, investors evidently see 5% as too generous. Whether the stock is cheap comes down to whether profit from the two drugs lasts long enough to justify that extra discount.

Dilution matters too. April 2026’s public offering issued 51,304,400 new shares, about 12.9% dilution against the existing share count. The simulated market cap above already uses the post-offering share count, but the owner earnings come from before the offering. Spread over post-offering shares, adjusted owner earnings are about 164 yen per share.

Net cash of minus ¥287bn, improving after the equity raise

Net cash here uses a conservative definition: (current assets − inventories) + investment securities × 70% − liabilities. It improved from −¥483.95bn in 2024 to −¥286.97bn in 2026, but it is still deeply negative, at roughly −640 yen per share. There is no balance-sheet cushion under the share price. Most of the improvement came from liabilities falling by ¥61.0bn, from ¥573.1bn to ¥512.1bn.

There is a timing mismatch to keep in mind. The 2026 figure in the table uses the March 2026 balance sheet, before the offering, while the share count is post-offering. Applying the same definition to the June 2026 balance sheet gives about −¥167.2bn (a reference figure that uses the fiscal year-end value for investment securities), or roughly −370 yen per share. The offering and refinancing retired subordinated bonds and removed Sumitomo Chemical’s debt guarantee. The equity attributable to owners of the parent ratio rose from 22.8% at March 2025 to 36.4% at March 2026 and 48.4% at the end of June.

The Boost 2028 medium-term plan targets an equity ratio above 50% at an early stage and a return to positive net cash. The direction is right, but for now this is a balance sheet that is getting better, not a stock protected by net cash.

Two-drug concentration, and a gap until the next pillars mature

The biggest risk is that profit is concentrated in two U.S. drugs. Management expects GEMTESA’s net price (GTN) to worsen in the fiscal year ending March 2027 because of restored coverage and the IRA. If MFN pricing or tariffs become concrete, the North American business that generates most of the profit takes a direct hit.

Recent numbers also call for caution. In Q1 of FY2027 (March), revenue was ¥129.5bn (+19.9%), but operating profit fell to ¥18.1bn (−11.0%) and operating cash flow was −¥7.4bn. Quarterly profit of ¥17.0bn (+51.7%) was lifted by foreign exchange gains. Management guides first-half net income to ¥26.0bn (−73.7%), which should make the loss of the one-off gain plain to see.

On capital policy, part of the shelf registration (up to ¥140.0bn or 60 million shares, valid through March 2027) may remain unused, so further dilution is a live risk. The company still pays no dividend. With Sumitomo Chemical as controlling shareholder, the parent-subsidiary listing is also a governance issue for minority holders.

On the pipeline, the plan assumes enzomenib (acute leukemia, launch target FY2027) and nuvisertib (myelofibrosis, launch target FY2028) take over from the two drugs. If either stumbles, there is a gap once ORGOVYX and GEMTESA peak. On the other hand, assets such as the iPS cell–derived Parkinson’s product and a universal influenza vaccine are options the current price barely reflects.

Wait for now, and use the interim results to test run-rate profit

Sumitomo Pharma cut deep after a ¥315bn loss and got back to record profit on two U.S. drugs. Even adjusted owner earnings of ¥73.37bn, with the one-off removed, imply value of about 2x market cap at a 5% required return. The stance here is still wait for now, for two reasons. First, management itself expects net income to fall 27.9% in FY2027, so run-rate profit after the one-off drops out has not yet been confirmed in reported numbers. Second, even the post-offering reference figure leaves net cash at about −¥167.2bn, so there is no downside protection, and the two-drug concentration still justifies an extra discount.

Bullish monitoring triggers

• At the October 30, 2026 interim results, North American sales keep growing by more than 15% year on year and the full-year core operating profit forecast of ¥91.0bn is maintained
• By March 2027, the equity attributable to owners of the parent ratio exceeds 50%, net cash on okuriru’s definition improves past −¥150.0bn, and enzomenib’s filing stays on track for an FY2027 launch

Warning / pass triggers

• Weaker GEMTESA net pricing, MFN pricing, or tariffs push quarterly North American sales below the prior year, or the full-year core operating profit forecast is cut
• An additional equity raise under the shelf registration, or a delay in enzomenib’s filing or a halted trial

This is neither “record profit, so it’s cheap” nor “deeply negative net cash, so it’s dangerous.” The call waits for interim results without the one-off gain, to see whether the two drugs’ earning power and the balance-sheet repair show up together.

Want to simulate the "fair value" of Sumitomo Pharma Co., Ltd.?

Interested in digging deeper into the financial data for Sumitomo Pharma Co., Ltd. featured in this article?

At okuriru.com, you can run simulations for Sumitomo Pharma Co., Ltd. based on Buffett-style "owner earnings." Enter your required rate of return (hurdle rate) to instantly calculate a theoretical stock price.

👉 Calculate Sumitomo Pharma Co., Ltd.'s theoretical stock price

Resolve the question "Is this stock fairly priced?" using your own criteria. CSV downloads of financial data are available too!